Results 91 to 100 of about 38,540 (306)

Bispecific antibody for lung cancer: mechanisms and clinical insights

Frontiers in Immunology
Lung cancer is a refractory malignancy. Although various therapeutic options, including targeted therapies, immune checkpoint inhibitors, and systemic chemotherapy, have significantly improved the prognosis of lung cancer patients, five-year survival ...
Wei Chen, Afang Zhou, Yunfeng Zhou
doaj   +1 more source

Entwicklung eines Inkubationssystems für ein inverses Mikroskop zur Langzeitbeobachtung von Zellkulturen in gekammerten Objektträgern [PDF]

, 2001
Trifunctional bispecific antibodies open up new immunological possibilities in tumour treatment. Prior to clinical application, comprehensive investigations using animal models and in vitro examinations need to be done.
A. Buchner, Lindhofer H., R. Riesenberg, Riesenberg R., W. Feicht, Zeidler R.   +5 more
core   +1 more source

Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy

Advanced Science, EarlyView.
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao, Zihan Deng, Yufei Liu, Li Liu, Deqiang Deng, Muyang Yang, Yuanyuan Geng, Yao Sun, Beilei Yue, Jonathan F. Lovell, Yushuai Liu, Lisen Lu, Honglin Jin   +12 more
wiley   +1 more source

A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus

BMC Biotechnology
Background The World Health Organization (WHO) recommends combination therapy with two non-overlapping monoclonal antibodies (mAbs) to enhance protection in Rabies post-exposure prophylaxis (PEP).
Zhigao Zhang, Jia Li, Guanfeng Lin, Shouchun Cao, Yingsong Wu   +4 more
doaj   +1 more source

Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection [PDF]

, 2015
With over 3.5 billion people at risk and approximately 390 million human infections per year, dengue virus (DENV) disease strains health care resources worldwide.
Barrett, Alan D, Brien, James D, Chiang, Cindy, Diamond, Michael S, Hiscott, John, Johnson, Syd, Lam, Chia-Ying Kao, Pinto, Amelia K, Sarathy, Vanessa V, Shresta, Sujan   +9 more
core   +2 more sources

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer [PDF]

, 2017
Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes ...
Abken, Hinrich, Bourquin, Carole, Castoldi, Raffaella, Chaloupka, Michael, Chmielewski, Markus, Endres, Stefan, Grassmann, Simon, Henkel, Jonas, Klein, Christian, Kobold, Sebastian, Niederfellner, Gerhard, Rothenfußer, Simon, Schendel, Dolores J., Schmollinger, Jan C., Schnurr, Max, Steffen, Julius, Sustmann, Claudio, Zeng, Yi   +17 more
core  

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

Advanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen, Junjie Deng   +10 more
wiley   +1 more source

Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from anthrax in mice [PDF]

, 2016
Bacillus anthracis, the causative agent of anthrax, secretes three polypeptides, which form the bipartite lethal and edema toxins (LT and ET, respectively).
Cheung, Gordon Y.C., Curiel, David T, Debatis, Michelle, Dmitriev, Igor P, Kashentseva, Elena A, Leppla, Stephen, Moayeri, Mahtab, Shoemaker, Charles B, Tremblay, Jacqueline M, Yeh, Anthony J   +9 more
core   +2 more sources

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source